Ypsomed and Mediq announced today that they completed the sale of mail-order retailer for diabetes care DiaExpert.
Germany-based DiaExpert specializes in insulin pump therapy. The companies previously announced the sale of DiaExpert in October. This sale allows Ypsomed to focus on the manufacture and sale of its own medical technologies.
That focus continues to narrow after last month’s announcement of the discontinuation of Ypsomed’s agreement with Eli Lilly. Lilly elected to stop their joint collaboration to enter the U.S. insulin pump market.
Get the full story at our sister site, Drug Delivery Business News.